Microbiome Research

Microbiome Research

Microbiome Research

The microbiome is the collective genome of microorganisms in a particular environment. The microbiome affects many areas of human health, from innate immunity to chronic health conditions such as obesity and diabetes, to neurological diseases such as Parkinson's and mental illnesses such as depression and anxiety. Not surprisingly, the understanding about the microbiome is growing, and research in this area is expanding. CD BioSciences is interested in this promising new landscape and is ready to support your microbiome clinical research.

Extensive Microbiome Research Treatment Experience

While microbiome-based clinical research has yielded encouraging clinical outcomes, many challenges still remain. Gaining access to the right microbiologist and patient databases is critical to the success of clinical trials. CD BioSciences has a team of microbiology experts, who has accumulated extensive experience in the full spectrum extensive of microbiome research and global clinical resources. This ensures the streamline regulatory and clincial processes, and accurately and timely capture the data you need to tackle these various challenges in clinical development.

Highlights of our experience in a wide range of microbiome indications, including but not limited to:

Microbiome Research Expertise
  • lostridium difficile
  • Colonoscopy prep
  • Crohn's disease
  • Gastritis
  • Irritable bowel syndrome
  • Liver cirrhosis
  • Non-erosive reflux disease
  • Traveler's diarrhea
  • Ulcerative colitis

Experience in Developing Microbiome Therapeutics

Effective clinical drug development for microbiome therapeutics requires interdisciplinary resources, professional experience and state-of-the-art facilities. With our comprehensive infectious disease clinical trial services, we have accumulated rich experience in the development of clinical biologics. From a complete IND support program, early preclinical drug development to clinical and commercial manufacture and release, we provide a wide range of standards and specialized laboratory services to complement and enhance drug development programs at every stage.

Our therapeutics development expertise include but not limit to:

  • AMP (Antibacterial Peptide) is a multifunctional peptide with basic biological effects, especially in eliminating pathogenic microorganisms.
  • FMT (fecal microbiota transplantation) is the transfer of biological materials containing minimally manipulated microbial communities from human donors to human recipients (including autologous use) with the purpose of affecting the recipient's microbiome.
  • LBP (Live Biotherapeutic Product) is a biological product that contains live microorganisms (such as bacteria or yeast) and may contain one or more strains of microorganisms from the same or different species of microorganisms.
  • Phagotherapy (or phage therapy) is the therapeutic use of phage in the treatment of pathogenic bacterial infections. Bacteriophages are more specific than antibiotics.

Microbiome Analysis for Clinical Studies

At CD BioSciences, we provide "One-Shop" microbiome analysis for clinical research - from planning to final reporting. Empowered by our proprietary sequencing platform, we can accurately analyze the microbiome of your research samples. These samples can come from different research areas and different organ sources, including:

Gut microbiome analysis

Gut microbiome analysis

Skin microbiome analysis

Skin microbiome analysis

Oral microbiome analysis

Oral microbiome analysis

Vaginal microbiome analysis

Vaginal microbiome analysis

CD BioSciences' scientists are dedicated to bringing together years of valuable experience to help our clients shorten the clinical trial journey. For further details, please don't hesitate to contact us.

Are you looking for a professional advisor for your trials?

Online Inquiry
×